Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a significant advancement with the results of a landmark study published in the peer-reviewed journal Pancreatology. The research, titled ' Towards Automating Risk Stratification of Intraductal Papillary Mucinous Neoplasms: Artificial Intelligence Advances Beyond Human Expertise with Confocal Laser Endomicroscopy 2 ', demonstrates that Artificial Intelligence (AI) model combined with Cellvizio ® needle-based confocal laser endomicroscopy (nCLE) technology significantly outperforms human experts in risk stratification of Intraductal Papillary Mucinous Neoplasms (IPMNs), a common type of pancreatic cyst.
The study aimed to compare the performance of 16 nCLE human experts with a novel AI algorithm (nCLE-AI) specifically designed for the sub-classification of a type of pancreatic cystic lesion with malignant potential. These findings build on the CLIMB study data presented this year at DDW, which demonstrated strong diagnostic performance of needle-based confocal laser endomicroscopy in differentiating benign from malignant or pre-malignant pancreatic cysts. Indeed, the latest results from the CLIMB study -spanning 17 endosonographers across 14 centers - have further reinforced the significantly superior diagnostic accuracy of Endoscopic Ultrasound-guided nCLE (EUS-nCLE) compared to the current standard of care 3.
'This study marks a pivotal moment in our ability to accurately risk stratify pancreatic cysts. The nCLE-AI model has shown remarkable potential to not only enhance diagnostic accuracy beyond current expert capabilities but also to standardize the interpretation of nCLE imaging," said Dr. Somashekar (Som) Krishna, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center, lead author of the publication."By providing a more precise and objective assessment, this technology can significantly aid clinical decision-making, helping to ensure that patients at high risk receive timely intervention while those with low-risk cysts may avoid unnecessary surveillance or surgery."
The results of the study on risk stratification associated with IPMNs cysts with malignant potential, detailed in the table below, show that the nCLE-AI model combined with revised Fukuoka Criteria achieves an Area Under the Curve (AUC) of 0.85, with a sensitivity of 78% and a specificity of 78%. This performance is significantly superior to that of human experts using the same criteria (AUC 0.64; p<0.01) and represents an improvement over the nCLE-AI model alone (p=0.02), clearly demonstrating the superiority of the AI-augmented approach for enhancing the detection of malignant cysts that need immediate intervention. The AI model continues to improve rapidly with additional nCLE sequences and data.
Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated:"These latest results, published by a group of highly skilled interventional endoscopists from multiple countries and institutions, under the exceptional leadership of Dr. Krishna, materialize our vision of nCLE enhanced by AI models, whether developed internally or by academic partners. Adding AI will certainly lead to a broader adoption of nCLE in the community of interventional endoscopists but will also open the door to risk stratification strategies, which are completely absent in today's standard of care. This strongly reinforces our conviction that nCLE is playing a pivotal role in the diagnosis and management of patients at risk of pancreatic cancer."
About pancreatic cysts
The prevalence of pancreatic cystic lesions in the adult asymptomatic population ranges from 2.4% to 24.3%. The large majority of pancreatic cystic lesions are discovered through incidental imaging, and it is estimated that 40% of cysts with no risk of carcinogenesis are operated on unnecessarily. More accurate classification methods, including risk stratification, are therefore needed earlier in the patient's diagnostic workup. Conventional diagnostic testing involves performing an endoscopic ultrasound (EUS) and then collecting and testing the cyst fluid through fine needle aspiration (FNA). In some advanced facilities, next generation sequencing (NGS) of cellular DNA may be performed to provide additional data. Although most facilities employ a combination of a range of conventional diagnostic methods, sensitivity, specificity, and accuracy remain insufficient, potentially exposing patients to misclassified cysts and unneeded surgical procedures
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
______________________________
1
2 https://doi.org/10.1016/j.pan.2025.05.011
3 https://doi.org/10.1016/j.gie.2025.03.851
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 hours ago
- Business Wire
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ('RSUs') representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
Yahoo
17 hours ago
- Yahoo
Chronosphere Named a Leader for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Observability Platforms
Chronosphere recognized based on Completeness of Vision and Ability to Execute NEW YORK, July 11, 2025 /PRNewswire/ -- Chronosphere, the observability platform built for control, today announced it has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Observability Platforms1. Chronosphere was recognized as a Leader based on Completeness of Vision and Ability to Execute. This marks the second consecutive year Chronosphere has been positioned as a Leader in the Magic Quadrant. "We believe that being recognized as a Leader in the Gartner Magic Quadrant for the second year in a row reinforces the impact we're making on modern engineering teams," said Martin Mao, CEO and Co-Founder of Chronosphere. "As data volumes grow and architectures become more complex, our platform gives organizations the control they need to deliver reliable services, operate efficiently, and scale with confidence—all based on open standards." Chronosphere's product portfolio includes its flagship Observability Platform and its fully integrated Telemetry Pipeline, giving users greater flexibility and vendor neutrality through open standards like OpenTelemetry. With Chronosphere, engineering teams can: Reduce data noise by streamlining data relevant to each role and service. Focus on the data that matters, reducing data volume and associated costs by an average of 84%. Quickly fix issues through guided troubleshooting and correlation across metrics, logs, and traces. Customers report 50% reduced time troubleshooting and 75% fewer incidents with Chronosphere. "Traditional observability solutions require you to keep and pay for all telemetry data, regardless of whether it's useful or not; however, Chronosphere turns this model on its head," continues Mao. "Chronosphere was built to weed out invaluable data, so what's kept in the system, paid for, and used for troubleshooting is the valuable data needed to understand your environment and to remediate immediately. In addition to this recognition in the Gartner Magic Quadrant, Chronosphere was named a Strong Performer in the 2024 Gartner® Peer Insights™ "Voice of the Customer" report for Observability Platforms.2 The Voice of the Customer report, based on aggregated reviews from users and decision-makers, recognized Chronosphere as a Strong Performer, tying for the highest overall rating among all recognized vendors with a 4.7 out of 5 score, based on 70 total reviews as of December 27, 2024. Below are two anonymized reviews of Chronosphere from the company's profile on Gartner Peer Insights™: "Chronosphere: A Comprehensive Solution for Tracking Metrics. Chronosphere provides a wholesome platform for logging and observability. We have used this product to generate dashboards to track various metrics for our services such as latency and QPS. The platform overall is extremely customizable and easy to use. Highly recommend it!" - Software Developer at a $1B+ software company "Chronosphere should be the go-to for Kubernetes monitoring. Chronosphere is a seamless integration with Kubernetes. For Kubernetes heavy products, it's hard to imagine a better fit." - DevOps Engineer at a $10B+ software company To read the full 2025 Gartner® Magic Quadrant™ for Observability Platforms report, download here. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose. Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved About ChronosphereChronosphere is the observability platform built for control in the modern, containerized world. Chronosphere empowers customers to focus on the data and insights that matter by reducing data complexity, optimizing costs, and remediating issues faster. Its Observability Platform reduces data volumes and associated costs by 84% on average while saving developers thousands of hours. Chronosphere's Fluent Bit-based Telemetry Pipeline product optimizes and simplifies observability and security log data. The product transforms logs at the source and routes them to any destination without lock-in. Recognized as a leader by major analyst firms, Chronosphere is trusted by the world's most innovative brands, including Robinhood, DoorDash, and Zillow. Follow and learn more at Follow at LinkedIn and X. 1 Gartner, Magic Quadrant for Observability Platforms, Gregg Siegfried, Padraig Byrne, Andre Bridges, Martin Caren and Matt Crossley, July 7, 2025. 2 Gartner, Voice of the Voice of the Customer for Observability Platforms by Peer Contributors, 24 December 2024. View original content to download multimedia: SOURCE Chronosphere Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
17 hours ago
- Business Wire
In a Time of Uncertainty for Higher Ed, MIT's Lori Glover Shares a Framework for Building Sustainable Partnerships
CAMBRIDGE, Mass.--(BUSINESS WIRE)--As colleges and universities face new challenges and shifting expectations, the Academic Leadership Group is hosting a timely session on how leaders can build lasting partnerships. As colleges face growing challenges, MIT's Lori Glover reveals a new framework to help higher ed leaders build lasting and effective partnerships. Share On Thursday, July 17, 2025, Lori Glover, Managing Director of Global Strategic Alliances at MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL), will share practical insights on designing durable, values-aligned collaborations. The session is part of ALG's Empowered Leader Webinar Series and is open to academic leaders across institutions. Drawing from her new book, Innovation Alchemy, Glover will introduce a clear framework for building partnerships that move beyond short-term gains. 'This is a chance to rethink how we engage across institutions and sectors,' said Lori Glover. 'Connecting industry and academia provides the fuel for the Innovation Supply Chain that enables economic growth and positive societal impact.' Glover has led many of MIT CSAIL's complex partnerships encompassing research, talent, professional programs, and the start-up ecosystem. She has a rare perspective on what works in high-stakes environments. 'Lori brings clarity to a space that often feels messy,' said Jennifer K. Stine, co-founder and president of the Academic Leadership Group, 'At a time when many are being asked to do more with less, her approach gives leaders a way forward that is strategic and actionable.'
